Biliary Atresia Clinical Trial
Official title:
A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia
The Children Liver Disease Research and Education Network (ChiLDREN) is conducting a clinical trial to evaluate whether long-term treatment with corticosteroids improves the outcome of the Kasai or gall-bladder Kasai in infants with biliary atresia. In this clinical trial, ChiLDREN is testing whether corticosteroid therapy following the Kasai will improve bile drainage and long term outcome in infants with biliary atresia. Subjects in this trial must start treatment within 72 hours of the Kasai procedure and be part of a prospective study of the natural history of biliary atresia also being conducted by ChiLDREN (http://www.clinicaltrials.gov/ct/show/NCT00061828?order=3).
This is a multi-center randomized, double-blinded, placebo-controlled trial to prospectively
determine the efficacy of corticosteroids on the outcome of infants with biliary atresia. The
trial will be conducted by the NIDDK-funded network of 15 clinical centers comprising the
Biliary Children Liver Disease Research and Education Network (ChiLDREN), whose goal is to
study the etiology, pathogenesis, diagnosis, and treatment of infants with biliary atresia.
For the trial, our overall hypothesis is that therapy with corticosteroids following
portoenterostomy (including gall bladder Kasai procedure) will improve bile drainage and
long-term outcome in infants with biliary atresia. This hypothesis will be tested through the
following specific aims and hypotheses:
Aim 1: To determine whether corticosteroid therapy decreases serum bilirubin concentration
after portoenterostomy.
Aim 2: To determine whether corticosteroid treatment after portoenterostomy will improve
outcome as defined by survival without transplantation at 24 months of age.
Aim 3: To determine whether corticosteroid treatment after portoenterostomy will improve
growth of infants with biliary atresia.
Aim 4: To determine whether corticosteroid treatment improves biochemical indicators of each
of the fat-soluble vitamins after supplementation with standard doses.
Aim 5: To determine whether corticosteroid treatment after portoenterostomy will decrease the
incidence of persistent ascites or ascites that requires medical treatment.
The significance of the proposed trial is that it will determine whether corticosteroids are
an effective medical treatment to improve bile drainage and long-term outcome, and whether
its use reduces the need for liver transplantation in infants with biliary atresia.
Subjects will be recruited from patients enrolled in the ChiLDREN prospective observational
database study who undergo portoenterostomy or portochelecystostomy (gall bladder Kasai) for
biliary atresia.
The Primary outcome measure is the percentage of patients with serum total bilirubin <1.5
mg/dL and with native liver at 6 months after portoenterostomy.
Secondary outcome measures are:
1. Serum total bilirubin concentration (and also at 3 months after portoenterostomy)
2. Survival with native liver at 24 months of age
3. Growth
1. Weight for age Z-score (in patients without ascites)
2. Height for age Z score
4. Serum biomarkers of sufficiency of fat-soluble vitamins
1. Vitamin A: molar ratio of serum retinol/retinol binding protein
2. Vitamin D: serum level of 25-hydroxy vitamin D
3. Vitamin E: ratio of serum vitamin E/total lipids
4. Vitamin K: International Normalized Ratio (INR)
5. Presence of ascites
All measurements will be made at 12 and 24 months of age (unless noted otherwise):
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03667534 -
Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
|
||
Completed |
NCT02652533 -
Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
|
||
Completed |
NCT01443572 -
The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation
|
N/A | |
Recruiting |
NCT04373941 -
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia
|
Phase 2 | |
Completed |
NCT01854827 -
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
|
Phase 1/Phase 2 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Recruiting |
NCT05848310 -
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
|
||
Recruiting |
NCT05072626 -
High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
|
||
Completed |
NCT02292862 -
Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation
|
N/A | |
Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Recruiting |
NCT06184971 -
Biliary Atresia Research Network Northeast
|
||
Recruiting |
NCT04260503 -
Gut Microbiome in Biliary Atresia
|
||
Not yet recruiting |
NCT06260566 -
Tolerability of Enteral NAC in Infants
|
Phase 1 | |
Completed |
NCT01322386 -
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
|
Phase 1 | |
Recruiting |
NCT05909033 -
Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
|
||
Completed |
NCT03499249 -
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
|
Phase 2 | |
Recruiting |
NCT00345553 -
Biliary Atresia Study in Infants and Children
|
||
Recruiting |
NCT05521152 -
Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
|
Phase 3 | |
Not yet recruiting |
NCT05783518 -
Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06121375 -
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
|
Phase 2/Phase 3 |